Trial Profile
A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, Failing or Ineligible for First-Line Therapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2018
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ONTAK
- 25 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 25 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 13 Apr 2010 Planned end date (1 Dec 2011) as reported by ClinicalTrials.gov record.